Oventus Medical Ltd (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. The record date to be registered as a shareholder for participation in the SPP is Wednesday, 21 June 2017.
Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nCPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
Oventus Medical Limited (ASX:OVN) announces that it has completed a first tranche placement of approximately 18 million shares to institutional and sophisticated investors at an issue price of $0.36 per share to raise approximately $6.5 million.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a world-wide distribution agreement with Hong Kong based Modern Dental Group (HKG:3600). This is in addition to the recent announcement of the co-manufacturing agreement between Oventus and Modern Dental.
Oventus Medical Ltd (ASX:OVN) is pleased to announce that low pressure CPAP without a mask is one step closer. Results from the initial pilot study generated significant interest when presented at the American Academy of Dental Sleep Medicine in Boston on June 2nd 2017. The conference is the premier world forum for the latest developments in dental sleep medicine.
Oventus Medical Ltd (ASX:OVN) are pleased to announce that C-PAP (Continuous Positive Airway Pressure) without a mask is one step closer signalling the first major change in sleep medicine in decades. The first patient has been recruited in the next stage of a trial combining an oral appliance and C-PAP.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a manufacturing agreement with Hong Kong based Modern Dental Group. Modern Dental have extensive expertise in the manufacture of dental appliances and hold the required quality management certifications for medical device manufacture.
The daily commute from Geelong to Melbourne just got a little more perilous with a new study warning one fifth of Australian adults have fallen asleep while driving. Research from the Sleep Health Foundation also shows nearly a third of Australians drive while drowsy at least once a month. They're figures Geelong dentist Dr Joseph Juric said are only scratching the surface.
Treatment for sleep apnoea usually involves either a mask or a mouthguard. A new Australian invention combines the best elements of both. Brisbane dentist Chris Hart spent years struggling to sleep. He snored constantly. He often woke up during the night because he had stopped breathing because of a n obstruction in his nose and throat.
Oventus Medical Ltd (ASX:OVN) is pleased to provide the Company's latest Investor Presentation.
Australian medical device company Oventus Medical Ltd. (ASX:OVN), has lodged an FDA 510k submission for its O2Vent W device - an oral appliance intended to reduce or alleviate snoring, mild to moderate obstructive sleep apnoea and severe sleep apnoea when the patient is intolerant to Continuous Positive Airway Pressure Devices.